Suggestions
Dr Mike Nicholds
Chief Executive Officer at Newcells Biotech Ltd
Dr. Mike Nicholds is an experienced executive currently serving as the Chief Executive Officer at Newcells Biotech Ltd, a position he has held since June 2015.1 With over 30 years of experience in the life sciences industry, Dr. Nicholds has built an impressive career spanning various senior management and leadership roles.2
Career Highlights
Education and Background: Dr. Nicholds was trained as a microbiologist and began his career during the early years of the biotechnology industry.2 He initially worked in technical fields before transitioning into sales, marketing, business management, and executive director roles.
Current Role: At Newcells Biotech Ltd, Dr. Nicholds leads a company that specializes in:
- Producing induced pluripotent stem cells (iPSCs)
- Differentiating iPSCs into various cell and tissue types
- Providing high-quality cells and services for drug discovery and pre-clinical development1
Previous Positions: Throughout his career, Dr. Nicholds has held several notable positions, including:
- Managing Director at Cels Business Services Ltd (2005-present)
- Commercial Director at Avecia Biotechnology (2004-2006)
- Business Development Director at Avecia Inkjet Printing Materials (1999-2004)
- Strategy and Acquisitions Director at Zeneca LifeScience Molecules (1991-1999)
- VP Sales and Marketing at Chirex (1999)1
Expertise and Specialties
Dr. Nicholds has developed a wide range of skills and expertise, including:
- Strategy development and implementation
- Non-executive and executive board experience
- Fund raising
- Acquisition and licensing
- International business development
- Start-up and technology commercialization1
His passion lies in translating life sciences into practical products, such as biocatalysts, biologics, vaccines, and stem cells. Dr. Nicholds has worked with and advised companies of various sizes, from large corporations to medium-sized businesses and start-ups, including ICI, Zeneca, Avecia Biologics, and Chirex.2